VALANX Biotech

📣 Major milestone news from VALANX Biotech! We are absolutely delighted to announce promising in-vivo results for our lead program VLX101, demonstrating pre-clinical efficacy in treating T-cell mediated autoimmune diseases. This breakthrough underscores the potential of our novel protein conjugate therapy and innovative site-specific conjugation technology. ✨ 🔬 This has been years in the making and we could not be more thankful to our team and supporters who made this possible along the way. 🤟 🔎 Explore the full press release and learn more about our cutting-edge work at: https://lnkd.in/e4RSMTPQ   #VALANXBiotech #BiotechInnovation #AutoimmuneDisease #ProteinConjugation #InVivoResults #DrugDevelopment #LifeSciences #Biotechnology #Healthcare

💡 Focus spotlight today on this 2022 publication: 📡 "Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors" It is becoming more and more apparent that quality and optimized conjugation procedures are crucial to make the best ADCs possible - with potential impact on a lot of unmet medical needs, like the one mentioned below in Glioblastoma. VALANX Biotech is proud to work on this mission - highly optimized ADCs by perfectly site specific conjugation with complete freedom to choose the conjugation site - allowing full range of optimization for patient benefit. #ADCs #proteinconjugation #therapeutics #cancer #oncology #antibodydrugconjugates https://lnkd.in/eS5AEbXB

🌟 Welcome Ursula Toth, our new Research Technician Downstream at VALANX Biotech! 🌟    Ursula holds a degree in Molecular Biotechnology from the FH Campus Wien | University of Applied Sciences and spent a decade researching tRNA biology and the enzymes involved in tRNA processing at the Medical University of Vienna. Ursula's passion for basic research is matched by her enthusiasm for applied science at VALANX, where she now contributes to the development of targeted cancer therapies. "Working on antibody treatments for targeted cancer therapies that can benefit patients soon is truly exciting," she shares. In her free time, Ursula enjoys sports, hiking, drawing, and practicing healing massage therapy. Welcome aboard, Ursula! We're thrilled to have you as part of the VALANX team! 🌞 🔬 #NewBeginnings #VALANXTalent #WelcomeToTheTeam

Our first stop on the conference circuit ✅   Our CEO, Michael Lukesch, presented our technology at #Sachs_ELSF. It was an amazing opportunity to showcase our innovative advancements in site-specific protein conjugation. 🧬 ✨   👇 Check out Michael's insights on this! https://lnkd.in/g7RyAcZU #VALANXBiotech #BiotechInnovation #SachsELSF 

🚀 Our leadership team is set to make waves at upcoming conferences! We are sharing latest breakthroughs in our cutting-edge site-specific protein conjugation tech here: • February 26-28, Boston, 3rd Next Generation Conjugates Summit, Georg Altenbacher attending •February 28-29, Zürich, Annual European Life Sciences CEO Forum, 10 Minute talk by Michael Lukesch • March 12 - 15, London, 14th Annual World ADC London, Poster presentation by Michael Lukesch •March 18-20, Barcelona, BioEurope Spring, Michael Lukesch attending •April 1-4, Washington D.C., World Vaccine Congress, Michael Lukesch attending  Stay tuned for insightful updates from VALANX Biotech! #Sachs_ELSF #WorldADC Antibody Drug Conjugates #WVC2024 #bioeurope #adcs #adc #antibodydrugconjugates #proteinconjugation #syntheticbiology #synbio

🎓 Congratulations to Lea Leitner on achieving her Master's Degree in Biotechnology at University of Natural Resources and Life Sciences, Vienna (BOKU)!    🌟 Lea produced VALANX' first Antibody-Drug-Conjugate (ADC) by transferring our technology into Chinese Hamster Ovary cells - a remarkable achievement. We are happy to have her staying on to continue her work to push the technology further. Well done, Lea! 🎉    #MastersDegree #BiotechnologySuccess #CongratulationsLea

As we wrap up this year, we are thrilled to welcome our newest team member, Adriana Fink, to VALANX Biotech! 🎉    Currently pursuing a Master's degree after completing a Bachelor's in Molecular Biology at the University of Vienna, she sees science as the intersection of curiosity and discovery. Fascinated by the intricate workings of biological networks, Adriana marvels at the seamless collaboration of processes within living organisms and cells. She finds joy in unravelling the complexity of systems, viewing it as a thrilling puzzle.   When not immersed in the world of science, Adriana loves doing sport, cooking and traveling the globe, exploring new cultures.   Welcome, Adriana! We are looking forward to your prosperity with us! 🔬✨ #NewBeginnings #VALANXTalent #WelcomeToTheTeam

🎄 A joyous holiday season and Happy New Year from the whole team at VALANX Biotech 🎄   🤗 Thank you for your continued support and partnership during 2023, which we highly appreciate.   🌟 🔬 We are very much looking forward to a dynamic and successful 2024 filled with innovation and transforming research into meaningful therapies.     With warm wishes, The team at VALANX Biotech

Hello! 👋 ✔ We are listed in a contest here. https://lnkd.in/dkeTHMM3 and highly appreciate your vote for VALANX Biotech if you think what we are doing is awesome. 💥 We certainly do. 👩⚕️ 👨⚕️ Thank you! 🙏

Congratulations to Marta Deneha for obtaining her Master’s Degree in International Business Administration at University of Vienna! Your journey was tough, but your determination prevailed. We take pride in your success! 🎓 🌟 #mastersgraduate #congratulations #valanxteam